Study design and participants
Cancer
ONCOLOGY, DISEASE, CANCER
This was a Phase II, open-label trial conducted at a single Australian centre (ACTRN12617001000392) within the framework of the Cancer Molecular Screening and Therapeutics (MoST) program [Patients were required to have an Eastern Cooperative Oncology Group performance status (ECOG PS) 0–2; evaluable disease by Response Evaluation Criteria in Solid Tumours (RECIST v1.1) [